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Medicaid, Medicare, and major insurance companies are being faced with increased costs for 
drug test screening. These costs are not caused by a spike in the use of narcotics by subscribers, 
but from unnecessary testing and overbilling by doctors and drug screening companies. 
Recovering drug addicts are required to have random drug tests during their treatment program, 
but instead of being random, the drug tests have become prescriptive. Testing is performed at 
specific times weekly on a single patient, for substances that return results that are unimportant 
to the doctors. Doctors are given drug testing kits by large drug testing companies that are very 
accurate and low in cost. Once the necessary drug tests are completed, the insurance companies 
are billed for thousands of dollars. The test results are received by the doctors who are able to 
confirm or deny the use of a particular drug. Next, the doctors send the exact test sample to a 
drug testing company or laboratory for further confirmatory testing. Medicaid, Medicare, and 
employers are billed twice by way of the insurance companies, for the same tests on a single 
patient on the same date of service; first from the doctor and then from the laboratory (The 
Pathology Blawg). My focus will be to examine the current drug test billing system, assess the 
risks and vulnerabilities faced by Medicare, Medicaid and the insurance companies and analyze 
and recommend strategies to detect and eliminate fraud, waste and abuse (FWA) caused from 






The History of Fraud, Waste and Abuse 
David Friedrichs in his book Trusted Criminals: White Collar Crime in Contemporary 
Society, states that medical facilities have defrauded the government of billions of dollars 
annually through federally funded healthcare programs. Frederichs also stated that in 1995 FBI 
Director Louis Freeh contented that health care fraud was the fastest growing crime in the United 
States. The federal government confirmed “that medical fraud accounted for between 3 and 10 
percent of the annual $1 trillion U.S. health care bill.” Taxpayers have been left to foot a 
significant portion of this tax bill (Fredrichs). 
Fraud is “knowingly and willingly executing, or attempting to execute, a scheme to defraud a 
health care benefit program.” Fraud is committed when money or property is obtained by means 
of false or fraudulent pretenses, promises or representations from organizations that administer 
health care benefit programs. 
Waste involves the over use of services or practices that result in unnecessary costs to the health 
care system. Waste is the misuse of resources; the actions of waste is not considered criminally 
negligent.  
Abuse includes any action that directly or indirectly results in unnecessary costs to the health 
care system. Incorrect payments are made for services not rendered or which did not meet 
professional standards. Healthcare providers and suppliers may unknowingly receive payments 
for which they are not legally entitled. This stems from the intentional misrepresentation of facts 
from subscribers, and thus makes abuse not easily identifiable. What constitutes “abuse” or 
“fraud” depends on specific facts and circumstances such as intent, prior knowledge, and 
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available evidence (Addressing Fraud, Waste and Abuse). 
The Impact of Fraud, Waste and Abuse on the Healthcare Industry 
Fraudulent claims are a big burden to the insurance industry. In 2011, The National 
Health Care Anti-Fraud Association (NHCAA) reported that “$2.27 trillion was spent on health 
care and more than four billion health insurance claims were processed in the United States.” 
The fraudulent claims among these processed claims are of a small percentage, yet the cost to the 
government is huge (NHCAA). 
The Centers for Medicare and Medicaid Services (CMS) anticipated total health care 
expenditures to reach $2.4 trillion in 2008. With the effects of demographics and the rising cost 
of medical treatment, total health care spending was projected to reach $4.14 trillion by the year 
2018. This amount accounts for a large amount of the gross domestic product. In 2007, the 
National Health Care Anti-Fraud Association estimated that health care fraud accounted for three 
percent or $68 billion of health care expenditure in the United States. For that same year, the 
Federal Bureau of Investigation (FBI) expected losses due to health care fraud was between three 
and ten percent; at ten percent the losses would reach $226 billion (Price).  
The FBI reports that health care fraud is a rising threat that costs the country tens of 
billions of dollars a year. National health care expenditures were estimated to exceed $3 trillion 
in 2014 with spending outperforming inflation (Health Care Fraud). These CMS statistics tells us 
that fraud has a devastating financial impact on health care organizations. An analysis done by 
the ACL Services Ltd., an audit and risk management transformation company, found that not 
only does fraud affect a company financially, but operationally and psychologically as well. 
Operationally, fraud disrupts the continuous work cycle of a company and psychologically, 
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employees become distrusting of each other and the providers and subscribers they serve. While 
the monetary loss is substantial, the full impact of fraud on an organization is overwhelming as 
these losses demoralize a company’s reputation, goodwill, and customer relations. An effective 
fraud management program is a guaranteed deterrent that will protect healthcare organization’s 
assets and reputation (Coderre).  
Fraudulent activities can be perpetrated by any employee within an organization or by 
external affiliates. As the NHCAA states, whether subscribers have an employer-sponsored or a 
self-funded insurance plan, health care fraud unavoidably translates into higher premiums and 
out-of-pocket expenses as well as reduced benefits or coverage. For both private and government 
employers, health care fraud increases the cost of providing insurance benefits for employees and 
the overall cost of doing business. This increased expense is an added burden, especially to 
households with minimal residual income, and will force many Americans to make the decision 
as to whether or not health insurance is purchased for their households (NHCAA). 
 A September 2009 article in the Journal of the American Academy of Psychiatry and the 
Law, indicated that health care fraud is not a victimless crime. Health care companies will 
attempt to recoup sustained losses and all costs associated with this are passed on to the 
subscribers. The diversion of funds due to fraud increases the costs of providing legitimate 
medical services, while decreasing an organization’s net income. Providers will institute 
mechanisms designed to recoup these losses and these mechanisms will sometimes include 
unethical practices. Health insurance companies may reduce benefit coverage while self-funded 
individuals will pay higher premiums. The federal government may change eligibility 
requirements for programs such as Medicaid, and employers may request higher copays from 
their employees. Physicians may compromise patient safety and perform unnecessary procedures 
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and will bill for services never rendered. A false medical history is created and patients may later 
sustain difficulties obtaining disability or life insurance policies. An inaccurate medical history 
influences treatment decisions, and some insurance companies may deny coverage to subscribers 
based on a medical condition that does not exist. The medical profession is one of the most 
ethical professions in the United States; health care fraud tarnishes this reputation and raises 
questions about the ethics governing the profession as a whole (Price). 
Provider Healthcare Fraud 
The NHCAA indicates that the majority of health care fraud is committed by a small 
minority of dishonest health care providers. Fraudulent providers take advantage of the 
confidence entrusted to them by their patients. The actions of these providers destroy the 
reputation of perhaps the most trusted and respected physicians in our society. Physicians have 
access to patients’ records and a wide range of medical conditions and treatments with which to 
perpetrate a fraud scheme. Unlimited access to medical codes and patients who need constant 
treatment, gives the provider the ability to submit false claims for numerous insurers. 
Distributing false or fraudulent claims among insurers sponsored by public programs such as 
Medicare and Medicaid, increases fraud proceeds while lessening the chances of these providers 
being detected. 
According to the NHCAA, dishonest providers commit fraud by: 
• Billing for services that were never rendered. Genuine patient information may be 
obtained through identity theft to fabricate entire claims or legitimate claims are padded 
with charges for procedures or services that did not occur. 
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• Upcoding thus billing for more expensive services or procedures than were actually 
provided or performed. Providers will inflate a patient’s diagnosis to a more serious 
condition and falsely bill insurers for a substantially higher-priced treatment than was 
actually provided. Performing medically unnecessary services solely for the purpose of 
generating insurance payments is often seen in fraudulent nerve-conduction and other 
diagnostic-testing claims. 
• Non-covered treatments are misrepresented as medically necessary and covered for the 
purposes of obtaining insurance payments. In cases such as cosmetic-surgery schemes, 
non-covered cosmetic procedures such as nose jobs are billed to patients' insurers as 
deviated-septum repairs. 
• Unbundling - each step of a procedure is billed as if it was a separate procedure. This is 
seen in the treatment of drug addicts when drug tests from a single blood sample that 
detect a variety of narcotics is separated into multiple tests and billed separately. 
• Patients are billed for more than, or for the co-pay amounts for services that are paid in 
full by the benefit plan. 
• Providers may accept kickbacks from treatment facilities or hospitals for patient referrals. 
• Providers may waive patient co-pays or deductibles for medical or dental care and over-
bill the insurance companies. Policies set by insurers with regard to co-pay waivers are 
ignored by providers, thus violating the contracting process. Medicare prohibits routinely 
waiving co-pays unless it’s due to financial hardship (NHCAA). 
 
8 
The Concept of Drug Screening and Confirmatory Tests 
According to the Substance Abuse and Mental Health Services Administration 
(SAMSHA), an agency of the U.S. Department of Health and Human Services, drug testing is 
typically a two-step process involving an initial drug screen done to identify possibly positive 
and negative specimens. A confirmatory test follows the initial screening to analyze any positive 
specimen detected. Screening tests, also known as initial tests, indicate the presence or absence 
of a specific substance or one that is chemically similar. These are qualitative analyses that 
confirm if the drug is absent or present in a particular specimen. Blood, urine and saliva are the 
most common specimens. Screening tests done in a laboratory or onsite in a physician’s office, 
are referred to as point-of-care tests (POCT). These tests are inexpensive, easily automated, and 
produce immediate results. Technological advances have led to improvements in confirmatory 
tests, giving laboratories the option to bypass screening tests and use confirmatory tests for 
specimen analysis (USDHHS). 
Medicare Fraud in Drug Test Screening 
The Wall Street Journal reports that medical providers are cashing in on costly drug tests 
that are unnecessary and billing Medicare for these costs. Doctors are conducting unnecessary 
drug tests on seniors for opiates such as heroin, cocaine and angel dust which few use. These 
tests are totally unnecessary and Medicare is billed for these test costs. Doctors are encouraged to 
operate by medical guidelines when treating patients, especially for pain, and test these patients 
to make sure they are neither abusing pills nor failing to take them. Unscrupulous pain doctors 
are making more from testing patients than from treating them. 
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Medicare became aware of abusive practices being carried out during simple urine tests 
and changed its billing procedures. Some doctors moved on to high-tech testing methods, where 
billing wasn’t limited and started testing for a variety of different drugs. Medicare or Medicaid, 
the federal health program for the elderly and disabled, is billed separately for each substance. In 
the Wall Street Journal report, the writer states that one provider who owns a laboratory and does 
high-tech tests for physicians, believes that testing for a broad range of drugs makes sense. High-
tech tests are more accurate than single tests. These tests lessens the risk of missing substance-
abusers. Medicare spent $445 million on 22 high-tech tests for drugs of abuse in 2012, and $14 
million for angel dust or PCP testing; this amount increased 1,423% in five years (Weaver). 
Case Study 1 
Calloway Laboratories 
In April 2012, Calloway Laboratories of Woburn, Massachusetts agreed to pay $20 
million dollars to the state to settle charges that it defrauded Medicaid out of millions of dollars 
through an elaborate kickback scheme involving sham companies, fake doctor signatures, and 
excessive urine testing for impoverished drug addicts. Two executives of Calloway Laboratories, 
chief executive officer Arthur Levitan and chief operating officer Patrick Cavanaugh, as well as 
two employees of sober homes (group homes for recovering drug addicts) were indicted by a 
grand jury on charges involving the creation of straw companies. These straw companies were 
used to funnel bribes to the managers of sober homes, and in return for these bribes, the 
managers allegedly required tenants to undergo excessive urine screening. The lab work was sent 
to Calloway Laboratories and paid for by Medicaid. Much of the lab work was not ordered by a 
doctor or authorized medical provider as required by law, and claim documents included falsified 
doctors’ signatures (Wen). 
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Arthur Levitan and Patrick Cavanaugh along with William Maragioglio, an associate who 
owned and operated a sober home, were sentenced to four years of probation for a kickback 
scheme that cost the state Medicaid program millions of dollars (Conaboy). Under the settlement 
made by Calloway Laboratories, Arthur Levitan and Patrick Cavanaugh were no longer 
employed by or allowed to consult for Calloway Laboratories. The company agreed to a three-
year compliance and monitoring program by the state of Massachusetts (Wen).  
In May 2014, Calloway Laboratories again settled a lawsuit with the state of West 
Virginia for false billings submitted to West Virginia Medicaid and nationwide to Medicare. The 
investigation was conducted by the West Virginia Medicaid Fraud Control Unit (WV MFCU) 
and the United States Department of Health and Human Services, Office of the Inspector 
General (HHS-OIG). It was found that from March 2009 to April 2013, Calloway Labs billed 
Medicare and West Virginia Medicaid for false drug tests by using a pathology services code, in 
addition to the required code for urine drug testing. Calloway Labs performed a medical review 
with every urine drug screen, but billed Medicare and Medicaid for pathology services that were 
never rendered.  Medical reviews are not covered by Medicare or West Virginia Medicaid but 
Calloway Labs submitted these claims under false pretenses and collected payments.  A new 
management team brought on in 2012 by Calloway Labs’ new owners voluntarily discarded the 
company’s fraudulent billing practices (Justice News). 
Sober Homes 
Sober homes is an informal term used for rental homes marketed to recovering substance 
abusers. These homes are low-budget rooms found in apartment buildings or houses, usually in 
recession-plagued neighborhoods. Recovering addicts are guaranteed a safe environment which 
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assisted each individual with the resources necessary for recovery. Residents had to adhere to 
mandatory urine tests which are performed about three times weekly to uphold the zero-tolerance 
rule for substance abuse. Even with these stringent rules, addicts or tenants got high and were 
amazed to find out they were not penalized when the tests results came up positive. Contrary the 
house rules, the residents were not evicted by their landlords, but instead were used to keep the 
drug testing scheme afloat .The recovering addicts were the money-makers for the sober homes 
and private drug-testing labs. This was a little-known niche of the drug testing world. Landlords 
needed the labs so they could prove their seriousness about sobriety, and largely to get referrals 
so the rooms of the sober homes will be continually filled. On the other hand, the labs needed 
access to numerous deprived substance abusers whose drug-screening tests qualified for lucrative 
Medicaid reimbursements that are worth millions of dollars annually (Wen).  
During a 2011 investigation by the Attorney General of Massachusetts, it was found that 
the owners of sober omes were accepting bribes from a renowned Massachusetts doctor, 
Punyamurtula Kishore. Dr. Kishore was arrested for falsely billing the State of Massachusetts $4 
million in Medicaid reimbursements (Wen). The sober homes involved, required the recovering 
addicts housed in their facilities to submit to urine drug screens at least three times weekly. 
These urine tests had to be performed by the physician office laboratories owned by Dr. Kishore 
at a cost of approximately $100 to $200 per test (Karpinsky). (Appendix D gives the link to the 
author, Patricia Wen’s account of her recorded interview with Dr. Punyamurtula Kishore and his 




Case Study 2 
Preventive Medicine Associates 
Dr. Kishore is the founder of Preventive Medicine Associates. Dr. Kishore owned and 
operated 29 treatment facilities throughout the state of Massachusetts, where each clinic 
specialized in opiate addiction treatment using a medication called Vivitrol. Patients suffering 
from opiate addiction were conventionally treated with methadone or Suboxone therapy. 
However, Dr. Kishore claimed that Vivitrol was a safer non-addictive form of treatment (Wen). 
In 2011, Dr. Kishore and Preventative Medical Associates were indicted and each charged with 
eight counts of Medicaid Kickbacks, eleven counts of larceny and eight counts of Medicaid False 
Claims to sober homes. The investigation was conducted by the Attorney General of 
Massachusetts and in 2013 additional charges of eleven counts of Medicaid False Claims and 
eleven counts of larceny were added to the original counts (Fennimore). New Horizon House is a 
sober home situated in a Quincy, Massachusetts. The home had strict rules against relapsing and 
required all residents to use Dr. Kishore, or one of his associates, as their primary care doctor. 
Recovering addicts were scheduled to submit three urine samples each week, with each test 
performed at Preventive Medicine Associates. Urine testing is typically paid for by Medicaid 
with remuneration ranging between $100 to $200 for each urine screen, as long as a doctor signs 
a form stating the test is medically necessary (Wen). 
Dr. Kishore’s approach to sobriety is known as The Massachusetts Model. This regimen 
of drug testing differed from what many top addiction specialists, including John F. Kelly of the 
Center for Addiction Medicine at Massachusetts General Hospital, recommend for most 
recovering addicts in sober home settings. Normal procedures used to prove if a substance abuser 
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has relapsed is doing random drug testing unbeknownst to the addict; not scheduled weekly 
testing as conducted by Dr. Kishore’s facilities. Dr. Kishore’s sales pitches to sober homes 
emphasized the fact that he was a medical doctor, and employed other doctors who could 
properly authorize drug tests. Dr. Kishore distributed literature that promoted his labs and 
compared his clinics to other commercial labs. The literature claims that commercial labs 
“Performs testing, then asks for referral after the fact (illegal),” while his labs “require a 
complete physical, obtain a complete patient history, then order and perform testing (legal).” Dr. 
Kishore began attracting more business from sober home managers as he was seen as a dedicated 
doctor willing to focus on substance abusers (Wen). 
“Precision Testing Laboratories”, a competing laboratory, filed a lawsuit claiming 
Dr. Kishore’s labs stole a number of its sober home clients including New Horizon. Precision’s 
lawyers subpoenaed Dr. Kishore’s bank records and found about a dozen $1,000 checks paid to 
New Horizon House for “facility fees.” These payments were viewed as bribes, even though they 
were veiled as salaries for no-show jobs and fees for alleged bed rentals or space in sober homes. 
Some of these checks were drawn on an account in the name of a nonprofit institution known as 
the National Library of Addictions. Dr. Kishore created this institution as an educational 
resource for drug treatment specialists. In all, the case involved more than 860 Medicaid 
recipients with more than 53,000 claims. Dr. Kishore and Preventive Medicine Associates pled 
not guilty and defended the payments to the sober homes as legitimate business expenses (Wen).  
In April 2015, Dr. Kishore pled guilty to all counts of his indictment and will serve 11 
months in jail with a ten year suspended sentence. In addition, Dr. Kishore and Preventative 
Medical Associates will pay $9.3 million in restitution for operating a Medicaid fraud scheme. 
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Dr. Kishore agreed to surrender his medical license (Fennimore). (Appendix B shows the 
revenue stream for the companies in both case studies.) 
Oversight and Internal Controls for Drug Screening Claims in the State of Massachusetts   
The Medicaid program in the state of Massachussets, known as MassHealth, is 
administered by the Executive Office of Health and Human Services (EOHHS). Between July 1, 
2008 and June 30, 2011, the Office of the State Auditor conducted an audit of MassHealth due to 
increased fraudulent activity against Medicaid; especially the frauds committed by Preventative 
Medicine Associates and Dr. Punyamurtula Kishore. MassHealth was developed to provide 
yearly access to healthcare services for low and mid income families. MassHealth’s upsurge in 
healthcare costs are due particularly to claims for drug test billing, as since 2007 MassHealth’s 
expenditures have risen annually on average by 8.69%. According to the Official Audit Report, 
in 2011 MassHealth paid healthcare providers more than $11.1 billion. An estimated 40% of this 
expenditure was funded by the state.  
MassHealth’s services include providing drug tests for subscribers with substance abuse 
disorders. Payments are made to physicians who directly order and authorize drug tests or to 
members who are being actively treated. MassHealth established internal controls over the 
payment process for laboratory drug tests, to ensure payments are made only for medically 
necessary drug tests claims. The objective of this audit on MassHealth was to ascertain: 
 If drug testing claims paid by MassHealth were medically necessary for subscribers 
with substance abuse disorders. 
 If required documentations were submitted to substantiate these claims. 
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 Whether the services being billed were actually provided.  
 If the billing and payment process conformed to the Massachusetts’ state laws and 
MassHealth’s policies.  
 If cost savings incentives and strategies were utilized.  
The audit on MassHealth generated the following findings: 
• MassHealth paid for drug tests allocated to members on a daily basis for extended 
periods, sometimes surpassing a year. This process deviated from the guidelines 
recommended by the federal Substance Abuse and Mental Health Services 
Administration (SAMHSA), and those of other substance abuse treatment professionals. 
It was found that MassHealth could have saved approximately $7.8 million if the State’s 
policies and procedures were adhered to.  
• Three laboratories were audited and it was discovered that “unbundling” was used when 
billing for drug testing services. Unbundling occurs when a group of drug testing 
procedure codes are billed separately. Contrary to Federal and State laws, this group of 
procedures must be billed using an all-inclusive procedure code. For four fiscal years 
ending June 30, 2012, unbundling costs to the State of Massachusetts totaled 
approximately $4.5 million. 
• A glitch in MassHealth’s claims processing system prevented claims for duplicate drug 
tests from being denied. Currently healthcare providers are permitted to test members 
with substance abuse disorders once daily. Approximately $286,000 was expended for 
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15,606 instances where MassHealth paid for claims submitted for the same member on 
the same day. 
• Pricing changes for drug tests approved by the state were not effectively implemented by 
MassHealth. On February 1, 2009, MassHealth had a price reduction in standard 
multiclass drug tests, but these pricing adjustments were not implemented until 9 days 
later, causing overpayments of $107,309 on 2,348 claims. 
• Documentation requirements instituted by MassHealth were not followed by the 
laboratories when submitting drug test claims. Laboratory order forms and test results 
were unavailable at two of the three laboratories where the audit testing was conducted. 
However, the laboratories were paid $41,258 for these services. Physician’s 
authorizations and diagnosis codes were missing, a breach of MassHealth’s policies. 
MassHealth’s 30-day testing period limit was violated as standing order forms were used 
for periods surpassing this limit. Instances were found where testing was done with 
incomplete or sometimes non-existent forms (Official Audit Report). 
Recommendations for Increased Oversight 
The losses incurred by MassHealth could have been avoided if its management had 
actively enforced its policies: seeing to it that the frequency with which members received drug 
tests were monitored, investigated providers who submitted unusually large numbers of claims 
for drug tests per member, and ensured that tests that were originated by physicians were for 
medically necessary purposes for the member that was actively being treated.  
The State Auditor recommended that MassHealth implement simple processes to detect 
deficiencies in its system to improve claims processing.  It was suggested that system edits, 
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programs designed to detect flaws in medical claim processing software, be developed to 
successfully prevent fraudulent claims for drug tests ordered during the residential monitoring of 
substance abuse patients. Claims submitted frequently for a particular member would be detected 
during processing, analyzed, and verified for adherence to state policies. In order to track the 
payment of claims for any member, it was recommended that proper identification of the 
provider be submitted. This includes the physician’s or treatment facility’s name, identification 
number, and the diagnosis code used for treatment.  
All claim information is housed in MassHealth’s data warehouse. Irregularities such as 
high-frequency drug testing would be easily identified which could improve the quality of claims 
processed within the Medicaid Management Information System (MMIS). If MassHealth 
develops new requirements such as specific drug testing codes and patient identification 
numbers, it would be impossible for laboratories to continually test a single subscriber and 
submit unnecessary claims. MassHealth would then be in line with state and federal standards 
governing the use of drug screening services.  
The Official Audit Report states that MassHealth should “monitor the frequency with 
which members receive drug tests and investigate providers who submit unusually large numbers 
of claims.” Constant monitoring by MassHealth will ensure that drug tests are done only when 
medically necessary, and are ordered by physicians who are actively treating members with 
substance abuse disorders. System edits for unnecessary laboratory tests will be developed to 
establish regulations, detect and disallow claims for same day drug screens and confirmatory 
drug tests.  
MassHealth will frequently review the system edits programmed in its claims processing 
software, to ensure that claims which violate state regulations will be readily identified. 
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Facilitating communication between MassHealth and healthcare or laboratory providers can 
alleviate all misunderstandings of how payments are processed for state provided services. 
Providers will be notified of duplicate verification tests and will be advised if these procedures 
are covered. The Office of the State Auditor recommended that Provider Bulletins outlining 
requirements for requesting laboratory services and recordkeeping be issued to laboratory 
providers (See Appendix F, 130 CMR 401.416 to 401.417, 410.455 to 410.459) (Official Audit 
Report).  
The recommendations given to MassHealth by the Massachusetts Office of the State 
auditor can be successfully applied not only to state administered insurance plans, but to 
insurance companies that administer state and employer funded plans. Having effective internal 
controls such as implementing system edits will prevent, detect and reduce any fraudulent claims 
submitted by a provider. Adding a data mining software to a claims processing system will 
monitor incoming claims, and reveal subscribers who have a large volume of drug test claims, 
over the amount considered normal for a specific period. 
Healthcare Fraud and Abuse Laws 
The Anti-Kickback Statute 
Jennifer Staman’s article in the Congressional Research Service states that the 
government was concerned that profit was a major influence for health care providers. Statues 
had to be enacted to protect federal healthcare programs from being financially violated. The 
anti-kickback statute was passed by Congress, making it a felony for anyone to deliberately 
profit or generate business from a federal health care program. Payments from a these programs 
derived from exploiting residents of sober homes or substance abusers is forbidden. Persons 
found guilty for arranging scheduled drug tests contrary to state or federal policies will be in 
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violation of the anti-kickback statute. Violators will be subject to imprisonment of up to five 
years or fined up to $25,000. Healthcare providers or drug testing laboratories will receive up to 
a one year suspension from participating in all federal health care programs (Staman). 
The False Claims Act 
The Federal False Claims Act (FCA) has been used to fight fraud against the U.S. 
government, recovering more than $12.1 billion within a four year span, from January 2009 to 
the June 2013 fiscal year. The FCA is used when prosecuting health care fraud cases and the 
Justice Department has imposed civil liabilities on providers, who knowingly submit false or 
fraudulent claims from billing services. These include services not provided, needless medical 
services, double billing or upcoding. Healthcare providers and laboratories will be fined a 
maximum of $11,000 per false claim filed and all additional damages incurred (Staman). 
Policies Instituted by Insurance Companies 
Two prominent insurance companies, AmeriHealth Caritas and Independence Blue Cross 
(IBC) are contracted by the government to provide cost-effective healthcare solutions for 
publicly-funded programs, such as Medicaid. On the company’s website, AmeriHealth Caritas 
states “it has made health care fraud prevention and detection a primary emphasis,” with an 
increased focus on preventing improper payments. Health care fraud is reduced when a 
prevention and detection fraud system is implemented instead of a pay and chase method of 
recovery for improper payments. Numerous processes are in place, all designed to prevent and 
detect fraud, waste, and abuse. These include: 
Preventive actions 
Multiple front-end system edit codes are used to detect recurring claims for specific subscribers 
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or drug testing providers. Claim alerts are initiated for high-dollar claims prior to disbursement. 
A pre-distribution review will ascertain the legitimacy of a submitted claim and authorizations 
must be received from subscribers or employers before payments are made to providers. 
Post-payment actions 
Medical claim data checks are done to analyze the frequency with which providers submit claims 
or use specific billing codes. Payment trend analysis is used to detect the frequency with which 
payments are made to providers. 
Corporate and Financial Investigations (CFI)  
Anti-fraud software is installed on claims processing systems to identify fraud, waste and abuse 
patterns. The detection of these patterns will allow the analysis of claims data to help identify 
improper payments. Pharmacy audits are conducted to see how often claims for high dollar drugs 
are made by any particular pharmacy (Fraud, Waste and Abuse). 
IBC has specific policies on presumptive and definitive drug testing. IBC’s decisions for 
coverage and payment of claims are based on the Centers for Medicare and Medicaid Services 
(CMS) regulations and guidelines. Presumptive drug tests are performed as baseline screenings 
and are done before or during a treatment process. Definitive drug tests are confirmatory tests 
ordered for verification if a presumptive test is positive. Providers have been successful in 
receiving fraudulent payments by double-billing insurance companies for negative presumptive 
drug tests and definitive tests on the same specimen. This is an unnecessary process as a negative 
presumptive test cannot result in a positive definitive test. IBC has implemented policies to 
eliminate double-billing by providers (IBC).  
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Presumptive Drug Testing 
Payment for presumptive drug tests are based on standards implemented for individuals 
receiving treatment for pain management or substance abuse. Presumptive drug testing is 
considered medically necessary, covered and paid for by IBC when an initial testing is 
conducted, during the treatment process, when an assessment of the member’s medical history is 
performed and treatment for substance abuse is found to be medically necessary. 
Definitive Drug Testing 
Definitive drug testing is conducted when it is ordered by a treating provider or when the 
presumptive test results are positive. The definitive testing is also conducted when a presumptive 
test result is negative and this finding is inconsistent with the individual’s medical history (IBC). 
Drug treatment facilities test residents via a single screen for up to 15 substances which cost 
$100 per screen. If the test returns positive for a specific drug, the 15 samples are sent for further 
confirmatory or definitive tests as individual samples. The insurance company will be billed 
$100 for the first single screen containing 15 samples, and then $1,500.00 for the 15 individual 
confirmatory tests (Lynne). This constitutes both fraud and waste as definitive tests are required 
only for positive preliminary test results. 
Covered Claims 
IBC policies state that drug testing is considered medically necessary and the company will 
cover 16 claims per calendar year. Consideration will be given to members who are believed to 
be continuing a pattern of substance abuse, and coverage will be extended beyond the 16 claim 
maximum.  
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Unnecessary Drug Tests 
Providers will submit claims for routine presumptive or definitive drug tests, whereby members 
are tested at every visit. Double testing is done by testing for the same drug with both a blood 
and a urine specimen at the same time. This is unnecessary and IBC has instituted system edits to 
detect multiple presumptive or definitive drug tests for members, and have also limited these 
tests to 120 times in a calendar year. (IBC). 
Conclusion 
Medicaid, Medicare and major insurance companies are being faced with increased costs 
for drug test screening. These costs are not caused by a spike in the use of narcotics by 
subscribers, but from unnecessary testing and overbilling by doctors and drug screening 
companies. The government is a major player in the healthcare industry as they are the principal 
payers of insurance claims and are susceptible to fraud. Employers who self-fund their 
employees’ insurance premiums are also vulnerable and have become joint victims to 
perpetrating providers. The healthcare industry needs to focus on prevention in order to eliminate 
fraud, waste and abuse in medical claim billing. Keeping ahead of technological advances is an 
effective way of reducing over billing in the industry. Diagnosis coding has been the weak link 
through which most fraud schemes have been perpetrated. These codes need to be updated 
regularly in accordance with nationally accepted coding guidelines, especially when new 
procedures have been implemented due to technological advances. This policy needs to be 
applied to all future applicable coding changes, revisions, or updates.  
Having effective internal controls over billing procedures is a deterrent and thus limits 
the chances providers may take to overbill the insurance company or the government. 
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Recovering drug addicts are required to have random drug tests during or as a part of their 
treatment program, but instead of being random, the drug tests have become precise. Testing is 
performed at specific times weekly on a single patient, for substances that return results that are 
unimportant to the doctors. If a weakness is found in a billing procedure, precautions should be 
taken to immediately change the billing structure or policies governing the structure. An open 
forum needs to be developed that gives providers a means of discussing any issue associated 
with the costs of administering drug tests. 
Doctors are given drug testing kits by large drug testing companies that are very accurate 
and low in cost. Once the necessary drug tests are completed, the insurance companies are billed 
for thousands of dollars. The test results are received by the doctors and they are able to confirm 
or deny the use of a particular drug. This exact test sample is then and there sent to a drug testing 
company or laboratory for further confirmatory testing. Medicaid, Medicare, and self-funding 
employers are billed twice by way of the insurance companies, for the same tests on a single 
patient on the same date of service; first from the doctor and then from the laboratory. 
Medical claims from providers should be routinely checked to ensure that the proper 
codes are being used for patients, and all providers made aware of changes to the policies and 
procedures of an insurance company or the CMS. The use of data mining software is an effective 
tool for conducting analysis, and identifying specific patterns in claim submission from providers 
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Abbreviations and Terminology 
CMS – Centers for Medicare and Medicaid Services 
DMA – Division of Medical Assistance 
EOHHS – Executive Office of Health and Human Services 
FBI – Federal Bureau of Investigation 
FWA – Fraud, Waste and Abuse 
IBC – Independence Blue Cross 
NHCAA – National Health Care Anti-Fraud Association   
MassHealth – Office of Medicaid 
MMIS – Medicaid Management Information System 
POCT – Point-of-Care Test 
SAMSHA – Substance Abuse and Mental Health Services Administration 
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HHS-OIG – United States Department of Health and Human Services, Office of the Inspector 
General 
USDHHS – U.S. Dept. of Health and Human Services 











































Boston Globe reporter Patricia Wen, gives a precise explanation how sober homes use drug 
addicts to fund their lucrative fraud scheme. Ms. Wen interviewed Dr. Punyamurtula Kishore, 
the founder of Preventive Medicine Associates, and owner/operator of 29 treatment facilities 
throughout the state of Massachusetts. Dr. Kishore was arrested and charged with eight counts of 
Medicaid fraud, 12 counts of larceny and with eight counts of illegal kickbacks to housing 
programs, known as sober homes, for recovering addicts. Ms. Wen interviewed Dr. Kishore at 
one of his offices. Her account of the interview can be seen here: 
Link: http://www.bostonglobe.com/metro/2012/03/31/seeking-help-but-finding-scam-sober-
homes/qmOkEiD4ZaUJ1Vf3NyZ8oJ/video.html?p1=Article_Video_More 















Preventive Medical Care – The Massachusetts Model 
The Chalcedon claims that Dr. Punyamurtula Kishore is arguably the twenty-first century's 
greatest pioneer in the treatment of substance addiction. Dr. Kishore developed 
the Massachusetts Model program which is characterized by a thorough and ongoing medical 
assessment of drug abuse patients and of multimodal therapeutic approaches. It may include full 
and comprehensive physical examinations, laboratory testing, toxicology, cardiac, neurological 
and pulmonary evaluations, education and support, and other methods. This program was 
claimed to far out-perform the existing treatment paradigms at vastly lower costs. The link below 

















130 CMR: DIVISION OF MEDICAL ASSISTANCE 
 
401.416: Request for Laboratory Services 
(A) Request Requirements. The independent clinical laboratory may not bill for a service 
unless it has received a written request to perform that specific service from an authorized 
prescriber who is treating the member and will use the test for the purpose of diagnosis, 
treatment, or an otherwise medically necessary reason as defined in 130 CMR 450.204. Any 
independent clinical laboratory billing for a service must maintain such request in its records, 
and 
make such records available to the MassHealth agency and the Attorney General's Medicaid 
Fraud Division upon request. If the laboratory that billed for the service cannot produce the 
original request, the MassHealth agency may deny or recover payment for all services the 
laboratory provided based on that request. 
(B) Standing Orders. An authorized prescriber may request an independent clinical laboratory 
to perform one or more tests on a single date, or issue a standing order for such tests. Standing 
order requests may not exceed 180 days in length with the exception of standing order requests 
for substance abuse testing, which may not exceed 30 days in length. Standing order requests are 
not permissible unless such repeated tests are medically necessary and required as part of the 
member's medical or drug treatment plan. 
(C) Required Information. Requests for laboratory services must be written and include the 
following information: 
(1) the date of the request; 
(2) the name or any other means of identifying the member to be tested; 
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(3) the name and address of the authorized prescriber (if the authorized prescriber is a 
Massachusetts Department of Public Health licensed substance abuse treatment program for 
the sole purpose allowed pursuant to 130 CMR 401.402, the request must include the names 
and addresses of both the substance abuse treatment program and the physician initiating the 
request); 
(4) the name of the specific laboratory tests to be performed; 
(5) the frequency for performing each laboratory test (applicable to standing orders only); 
(6) the duration and maximum number of times each laboratory test or tests are to be 
performed (applicable to standing orders only); and 
(7) a statement by the authorized prescriber that such testing is required as part of the 
member's medical or drug treatment plan (applicable to standing orders only). 
(D) Recordkeeping. If a laboratory refers a specimen to a testing laboratory, the referring 
laboratory must forward the original request to perform the service to the testing laboratory. The 
testing laboratory must maintain such request in its records in accordance with 130 CMR 
401.416(A). 
 
401.417: Recordkeeping Requirements 
Both referring and testing laboratories must keep a record of each written request for 
laboratory services, each specimen, and each test result for at least six years from the date on 
which the results were reported to the authorized prescriber. If the testing laboratory is a 
subsidiary-related entity of the referring laboratory, such records may be maintained at one 
location, but must be made available to the MassHealth agency and the Attorney General’s 
Medicaid Fraud Division upon request, in accordance with 130 CMR 450.205. If an independent 
clinical laboratory cannot produce the record to substantiate a MassHealth claim, the MassHealth 
agency may deny or recover payment for that claim. The laboratory record must contain the 
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following information: 
(A) The written request for laboratory services with all information required by 130 CMR 
401.416; 
(B) the identification number of the specimen; 
(C) the name or any other means of identifying the person from whom the specimen was taken; 
(D) the name of the authorized prescriber and, if applicable, the referring laboratory that 
       submitted the specimen. 
(E) the date on which the specimen was collected by the authorized prescriber or laboratory, 
      the location of the collection, and the name of the collector; 
(F) the date on which the specimen was received in the laboratory; 
(G) the condition of unsatisfactory specimens when received (for example, broken, leaked, 
      hemolyzed, or turbid); 
(H) the specific tests performed; 
(I)  the date or dates on which each test was performed; 
(J)  the results of each test, the name and address of all persons to whom each test result is 
      reported, and the date of reporting; and 
(K) the name and address of the laboratory to which the specimen was referred, if applicable. 
 
410.455:  Laboratory Services:  Introduction 
(A)  130 CMR 410.455 through 410.459 establish the requirements and procedures for clinical 
laboratory services provided by hospital outpatient departments.  A clinical laboratory service 
includes the following types of services:  microbiological, serological, chemistry, hematological, 
radioimmunoassay, cytological, immunological, pathological, or other examinations of materials 
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derived from the human body to provide information for the assessment of a medical condition 
or for the diagnosis, prevention, or treatment of any disease. 
(B)  The MassHealth agency does not pay separately for routine specimen collection and 
preparation for the purpose of clinical laboratory analysis (for example, venipuncture; urine, 
fecal, and sputum samples; Pap smears; cultures; and swabbing and scraping for removal of 
tissue.)  Specimen collection and preparation is considered part of the laboratory service. 
410.456:  Laboratory Services:  Payment 
(A)  Maximum Allowable Fee.  The maximum allowable payment for an acute or nonacute 
hospital outpatient department or hospital-licensed health center laboratory service is the lowest 
of the following: 
(1)  the amount in effect for the date of service in the DHCFP Clinical Laboratory Services fee 
schedule at 114.3 CMR 20.00 and 114.3 CMR 16.00;  
(2)  the amount that would be recognized under 42 U.S.C. 1395l(h) for tests performed for a 
person with Medicare Part B benefits; or 
(3)  the usual and customary fee. 
(B)  Usual and Customary Fee.  The term usual and customary means the lowest fee charged by 
a hospital outpatient department laboratory for any laboratory service (including both individual 
and profile tests) specified in the hospital outpatient department's charge book or by such 
hospital, with the exception of a fee offered for a bulk purchase.  (A bulk purchase is a single 
purchase of a laboratory service (one or more tests) to be uniformly and concurrently performed 
on a minimum of 40 specimens of the same type.  A single purchase of various, non-uniform 
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laboratory services, such as by a physician, is not considered a bulk purchase, regardless of the 
number of specimens presented by such a purchaser to the hospital outpatient department 
laboratory.) 
(C)  Profile or Panel Tests. 
(1)  A profile or panel test is any group of tests, whether performed manually, automatedly, or 
semiautomatedly, that is ordered for a specified recipient on a specified day and has at least one 
of the following characteristics. 
(a)  The group of tests is designated as a profile or panel by the hospital outpatient department 
laboratory performing the tests. 
(b)  The group of tests is performed by the hospital outpatient department laboratory at a usual 
and customary fee that is lower than the sum of that hospital outpatient department laboratory's 
usual and customary fees for the individual tests in that group. 
(2)  In no event shall a hospital outpatient department laboratory bill or be paid separately for 
each of the tests included in a profile test when a profile test has either been performed by that 
hospital outpatient department laboratory or requested by an authorized person. 
410.457:  Laboratory Services:  Request for Services 
The hospital outpatient department must have either a written requisition or a written order for 
the laboratory service signed by an authorized prescriber (that is, a licensed physician or dentist, 
or a registered nurse practitioner) before performing the service.  A written requisition signed 
only by an unauthorized prescriber is not acceptable.  Any failure or inability to make the 
authorized requisition or order available to the Division for review will be sufficient reason to 
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deny or recover payment for all services based on that requisition or order.  The hospital 
outpatient department may send disclosures concerning the test only to the prescriber, to the 
referring laboratory, if applicable, to the Division, and, at the written request of the prescriber, to 
the recipient. 
410.458:  Laboratory Services:  Recordkeeping Requirements 
In addition to meeting the recordkeeping requirements specified in 130 CMR 410.409, the 
hospital outpatient department must keep a suitable record of each specimen and laboratory test 
result for at least six years from the date on which the results were reported to the prescriber.  
Such a record must contain the following information: 
(A)  the name and any other means of identification of the person from whom the specimen was       
taken; 
(B)  the name of the prescriber or laboratory that submitted the specimen; 
(C)  the authorized requisition or order, or both; 
(D)  the location where the specimen was taken, if other than the hospital outpatient department; 
 (E)  the date on which the specimen was collected by the prescriber or laboratory; 
(F)  the date on which the specimen was received in the laboratory; 
(G)  the condition of unsatisfactory specimens when received (for example, broken, leaked,  
hemolyzed, turbid, or insufficient sample size); 
(H)  the date on which the test was performed; 
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(I)  the test name and the results of the test, or the cross reference to results and the date of 
reporting; and 
(J)  the name and address of the laboratory to which the specimen was referred, if applicable. 
410.459:  Laboratory Services:  Specimen Referral 
A hospital outpatient department may refer a specimen to an independent laboratory that is 
eligible to participate in the Medical Assistance Program, or to another hospital laboratory that is 
eligible to participate in the Medical Assistance Program.  To be eligible, a hospital laboratory 
must be in a hospital that is licensed by the Massachusetts Department of Public Health and that 
is an approved Medicare provider.  The referring hospital outpatient department laboratory must 
inform the prescriber of the name and address of the testing laboratory.  The testing laboratory 
must inform the referring hospital outpatient department laboratory of the results of the test.  
Only the referring laboratory is authorized to bill the Division. 
 
Source: Commonwealth of Massachusetts Provider Manual Series 
 
 
 
 
 
 
 
